Log In
BCIQ
Print this Print this
 

MK-1966

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
Description Anti-IL-10 immunomodulator
Molecular Target Interleukin-10 (IL-10)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard Indication Hematology (unspecified)
Indication DetailsTreat solid or hematological malignancies
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/01/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today